Roche's Diagnostics Momentum Meets a Xolair Reality Check
Published on 10/29/2026 at 14:51 | Editorial boerse-global.de
Roche has pushed its VENTANA BAP1 (SP527) test into worldwide availability, a launch that broadens the Swiss group's cancer diagnostics menu even as questions linger over pricing pressure in its established drug portfolio. The assay is designed to help pathologists diagnose mesothelioma and to separate malignant tissue changes from benign ones. It follows the CE marking of a new laboratory instrument announced earlier in the week, giving investors another concrete product milestone rather than a fresh revenue forecast.
A Diagnostic Tool, Not a Sales Number
The test carries Class I IVD registration with the US Food and Drug Administration and holds an IVDR Class C certification, according to Roche. Its intended role sits squarely in differential diagnosis: distinguishing a malignant mesothelioma from other tissue abnormalities. That places the announcement on the diagnostics side of the business rather than in the treatment column, and the distinction matters when weighing the news. A worldwide rollout expands the range of available products, but it does not by itself translate into a measurable contribution to group growth. Product availability and commercial impact have to be judged on separate tracks.
Two Steps, Two Different Statuses
Earlier in the week, on Tuesday, Roche Diagnostics disclosed CE marking for its cobas smart e immunoassay analyser, a device aimed at smaller laboratories and decentralised testing sites. The planned test menu runs to more than 100 assays, with over 90% of them intended to deliver turnaround times of 18 minutes or less. The two announcements serve different purposes within diagnostics. The VENTANA test is a targeted aid to cancer diagnosis and is already available globally. The cobas smart e is a laboratory platform whose menu Roche explicitly describes as planned — meaning the CE mark should not be read as full availability of every assay on the roadmap.
Clinical Data Behind the Pipeline
Sunday's release of the Phase III KRASCENDO 1 study supplied the clinical backdrop. Divarasib cut the risk of death by 44% versus sotorasib or adagrasib in previously treated KRAS-G12C-mutated non-small cell lung cancer, Roche reported, with median overall survival reaching 17.7 months against 12.0 months. Those results demonstrate a clinical advantage in the studied population; they do not constitute a regulatory filing. The diagnostics launch and the drug trial therefore sit at very different stages of development — one adds an available product, the other documents a benefit that still has to travel the approval path.
Should investors sell immediately? Or is it worth buying Roche?
The Numbers Behind the Headlines
On 22 October, Roche reported group sales of CHF 46.5 billion for the first nine months of 2026, up 6% at constant exchange rates. Third-quarter group sales grew 7% at constant currencies and 8% in CHF terms. The company reaffirmed its 2026 guidance: group sales growth in the mid-single-digit percentage range at constant exchange rates, with core earnings per share rising in the high single digits on the same basis.
That confirmed outlook sits alongside a clear soft spot. Reuters reported after the quarterly figures that Xolair sales disappointed following the launch of a cheaper copycat. Revenue for the drug came in at CHF 848 million in the third quarter of 2026, short of the CHF 925 million consensus. Encouraging pipeline news, in other words, does not erase competitive pressure on the existing franchise.
Analysts Split on the Story
Recent broker moves show no consensus investment verdict emerging from the flow of progress reports. JPMorgan lifted its price target to CHF 335 from CHF 325 on Monday while keeping a neutral rating; analyst Richard Vosser nudged his sales and earnings estimates higher after the quarterly update. Deutsche Bank was far more bullish on 23 October, upgrading Roche to Buy and raising its target to CHF 500 from CHF 340, citing positive physician feedback on Giredestrant.
Roche at a turning point? This analysis reveals what investors need to know now.
The takeaway for shareholders is that the BAP1 rollout adds an already-available product to the diagnostics line-up, while Xolair serves as a reminder of the limits of an exclusively upbeat reading. Clinical advances and the trajectory of mature medicines both feed into how the stock gets valued.
Ad
Roche Stock: New Analysis - 29 October
Fresh Roche information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
